In the aforementioned “A Phase I Clinical Trial of T-cells Expressing an Anti-SLAMF7 CAR for Treating Multiple Myeloma,” the authors have engineered a novel anti-SLAMF7 CAR capable of specifically recognizing and eradicating SLAMF7-expressing tumors in murine models. This evidence concerns the gene SLAMF7 and plasma cell myeloma.